# Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients

> **NCT04695470** · PHASE2 · UNKNOWN · sponsor: **Aiping Zhou** · enrollment: 70 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Fruquintinib and Sintilimab

## Key facts

- **NCT ID:** NCT04695470
- **Lead sponsor:** Aiping Zhou
- **Sponsor class:** UNKNOWN
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-06-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2021-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04695470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04695470, "Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04695470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*